Pyrroloquinoline Quinone Slows Down the Progression of Osteoarthritis by Inhibiting Nitric Oxide Production and Metalloproteinase Synthesis

Inflammation

Volumn 38, Issue 4, 2015, Pages 1546-1555

  Tao, Ran ^a   Wang, Shitao ^a   Xia, Xiaopeng ^b   Wang, Youhua ^a   Cao, Yi ^a   Huang, Yuejiao ^a   Xu, Xinbao ^a   Liu, Zhongbing ^a   Liu, Peichao ^a   Tang, Xiaohang ^c   Liu, Chun ^c   Shen, Gan ^d   Zhang, Dongmei ^c  

^a NANTONG UNIVERSITY   (China)

^b Emergency Department   (China)

^c NANTONG MEDICAL COLLEGE   (China)

^d THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

MMPs; NF B; NO; osteoarthritis; pyrroloquinoline quinone

Indexed keywords

COLLAGENASE 3; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE SYNTHASE INHIBITOR; PYRROLOQUINOLINEQUINONE; SYNAPTOTAGMIN I; MATRIX METALLOPROTEINASE-1, RAT; MMP13 PROTEIN, RAT; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL DAMAGE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; ENZYME SYNTHESIS; IN VITRO STUDY; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; DOSE RESPONSE; MALE; METABOLISM;

RATTUS;

ANIMALS; CELLS, CULTURED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; NITRIC OXIDE; OSTEOARTHRITIS; PQQ COFACTOR; RATS;

EID: 84937251214     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0129-x     Document Type: Article

References (30)

1. Kouri, J.B., and C. Lavalle. 2006. Do chondrocytes undergo “activation” and “transdifferentiation” during the pathogenesis of osteoarthritis? A review of the ultrastructural and immunohistochemical evidence. Histology and Histopathology 21: 793–802.
2. Loeser, R.F., S.R. Goldring, C.R. Scanzello, et al. 2012. Osteoarthritis: a disease of the joint as an organ. Arthritis and Rheumatism 64: 1697–1707.
3. Siebelt, M., H. Jahr, H.C. Groen, et al. 2013. Hsp90 inhibition protects against biomechanically induced osteoarthritis in rats. Arthritis and Rheumatism 65: 2102–2112.
4. Goldring, M.B. 2000. The role of the chondrocyte in osteoarthritis. Arthritis and Rheumatism 43: 1916–1926.
5. Wang, M., E.R. Sampson, H. Jin, et al. 2013. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Research & Therapy 15: R5.
6. Roach, H.I., N. Yamada, K.S. Cheung, et al. 2005. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis and Rheumatism 52: 3110–3124.
7. Kaspiris, A., L. Khaldi, T.B. Grivas, et al. 2013. Subchondral cyst development and MMP-1 expression during progression of osteoarthritis: an immunohistochemical study. Orthopaedics & Traumatology, Surgery & Research 99: 523–529.
8. Kobayashi, Y. 2010. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. Journal of Leukocyte Biology 88: 1157–1162.
9. Melchiorri, C., R. Meliconi, L. Frizziero, et al. 1998. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis and Rheumatism 41: 2165–2174.
10. Tomita, M., E.F. Sato, M. Nishikawa, et al. 2001. Nitric oxide regulates mitochondrial respiration and functions of articular chondrocytes. Arthritis and Rheumatism 44: 96–104.
11. Cake, M.A., R.C. Appleyard, R.A. Read, et al. 2003. Topical administration of the nitric oxide donor glyceryl trinitrate modifies the structural and biomechanical properties of ovine articular cartilage. Osteoarthritis and Cartilage 11: 872–878.
12. Marcu, K.B., M. Otero, E. Olivotto, et al. 2010. NF-kappaB signaling: multiple angles to target OA. Current Drug Targets 11: 599–613.
13. Saklatvala, J. 2007. Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Current Drug Targets 8: 305–313.
14. Stites, T.E., A.E. Mitchell, and R.B. Rucker. 2000. Physiological importance of quinoenzymes and the O-quinone family of cofactors. Journal of Nutrition 130: 719–727.
15. Salisbury, S.A., H.S. Forrest, W.B. Cruse, et al. 1979. A novel coenzyme from bacterial primary alcohol dehydrogenases. Nature 280: 843–844.
16. Felton, L.M., and C. Anthony. 2005. Biochemistry: role of PQQ as a mammalian enzyme cofactor? Nature 433: E10. discussion E11-12.
17. Killgore, J., C. Smidt, L. Duich, et al. 1989. Nutritional importance of pyrroloquinoline quinone. Science 245: 850–852.
18. Steinberg, F., T.E. Stites, P. Anderson, et al. 2003. Pyrroloquinoline quinone improves growth and reproductive performance in mice fed chemically defined diets. Experimental Biology and Medicine (Maywood, N.J.) 228: 160–166.
19. Bauerly, K.A., D.H. Storms, C.B. Harris, et al. 2006. Pyrroloquinoline quinone nutritional status alters lysine metabolism and modulates mitochondrial DNA content in the mouse and rat. Biochimica et Biophysica Acta 1760: 1741–1748.
20. Stites, T., D. Storms, K. Bauerly, et al. 2006. Pyrroloquinoline quinone modulates mitochondrial quantity and function in mice. Journal of Nutrition 136: 390–396.
21. Bauerly, K., C. Harris, W. Chowanadisai, et al. 2011. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PLoS ONE 6: e21779.
22. Sampson, E.R., C.A. Beck, J. Ketz, et al. 2011. Establishment of an index with increased sensitivity for assessing murine arthritis. Journal of Orthopaedic Research 29: 1145–1151.
23. Shiomi, T., V. Lemaitre, J. D’Armiento, et al. 2010. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathology International 60: 477–496.
24. Daheshia, M., and J.Q. Yao. 2008. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. Journal of Rheumatology 35: 2306–2312.
25. Takada, M., M. Sumi, A. Maeda, et al. 2012. Pyrroloquinoline quinone, a novel protein tyrosine phosphatase 1B inhibitor, activates insulin signaling in C2C12 myotubes and improves impaired glucose tolerance in diabetic KK-A(y) mice. Biochemical and Biophysical Research Communications 428: 315–320.
26. Kimura, K., M. Takada, T. Ishii, et al. 2012. Pyrroloquinoline quinone stimulates epithelial cell proliferation by activating epidermal growth factor receptor through redox cycling. Free Radical Biology and Medicine 53: 1239–1251.
27. Zhang, L., J. Liu, C. Cheng, et al. 2012. The neuroprotective effect of pyrroloquinoline quinone on traumatic brain injury. Journal of Neurotrauma 29: 851–864.
28. Burrage, P.S., K.S. Mix, and C.E. Brinckerhoff. 2006. Matrix metalloproteinases: role in arthritis. Frontiers in Bioscience 11: 529–543.
29. Rousset, F., M.V. Nguyen, L. Grange, et al. 2013. Heme oxygenase-1 regulates matrix metalloproteinase MMP-1 secretion and chondrocyte cell death via Nox4 NADPH oxidase activity in chondrocytes. PLoS ONE 8: e66478.
30. Kim, S.J., J.W. Ju, C.D. Oh, et al. 2002. ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. Journal of Biological Chemistry 277: 1332–1339.